New PET scans aim to spot prostate cancer more clearly
NCT ID NCT07365397
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests three new radioactive imaging agents against a standard one for PET/CT scans in 9 men with advanced prostate cancer. The goal is to see which agent best highlights cancer lesions in the body. It is an early-stage imaging study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-labeled PSMA probes (imaging agents)
What this could lead to
If successful, this could identify better imaging agents for detecting prostate cancer spread.
What could go wrong
This is a very small, early-phase study with only 9 participants, so results may not apply broadly. It focuses on imaging, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.